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Abstract 
Plasmacytoma is a rare hematological malignancy 
characterized by a discrete, solitary mass of 
neoplastic monoclonal plasma cells that occurs 
either (1) inside (solitary bone plasmacytoma - 
SBP) or outside (extramedullary plasmacytoma - 
EMP) the bone. Plasmacytoma mainly affects 
people in the 5th to 6th decade of their lives, and 
the incidence of the disease is higher in men than in 
women. It also affects African Americans more 
often than Caucasians, with the lowest incidence 
being reported in Asian populations. Unlike MM, 
plasmacytoma is not a systemic disease and lacks 
the characteristic CRAB abnormalities such as 
hypercalcemia, renal failure, anemia, and bone 
disease, excluding the plasmacytoma itself. The 
median time to progression of plasmacytoma to 
MM is 2-3 years, with progression more likely to 
occur in SBP than EMP. SBP commonly presents 
in the axial skeleton and mostly manifests as local 
pain, pathological fractures nerve compression, 
while EMP is usually seen in the head and neck and 
typically manifests as space-occupying lesions. 
Therapeutically, local therapy such as radiotherapy 
(RT) is the gold standard and is able to achieve 
long-term disease-free survival in approximately 
30% and 65% of patients with SBP and EMP 
respectively. Surgery (and adjuvant RT), on the 
other hand, is mostly reserved for easily resectable 
plasmacytomas. 
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Clinics and pathology 
Disease 
Plasma cell neoplasms can present as single lesions 
(plasmacytoma) or as multiple lesions in the 
context of end organ damage (active multiple 
myeloma (MM)).  
Plasmacytoma is a rare, infrequent plasma cell 
neoplasm that represents approximately 5-10% of 
all cases of this malignancy (Kilciksiz et al, 2012) 
and is characterized by the monoclonal proliferation 
of mature plasma cells that synthesize monoclonal 
immunoglobulins or free light chains (FLC).  
The disease, first described in 1905 by Schridde, 
exists in two forms known as solitary bone 
plasmacytoma (SBP) and extramedullary 
plasmacytoma (EMP) (Chang et al, 2014). SBP 
originates in the bone marrow, whereas EMP arises 
out of the bone marrow (Corvo et al). They are 
further distinguished by the location of their 
occurrence: SBP mainly presents as a single, 
typically painful bone lesion mainly occurring in 
the axial skeleton (83%), in such places as the 
vertebrae, with the other 17% of cases occurring in 
the appendicular skeleton, in such places as the 
pelvic bones.  
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EMP involves the soft tissue and usually manifests 
itself in the head and neck region (80% of cases; 
commonly of respiratory origin), and in the mouth 
and pharynx (Dores et al, 2009). The symptoms of 
each vary depending on the site of the malignancy. 
For SBP, the most common symptom is pain, with 
motor and sensory deficits occurring if the spine is 
involved. For EMP, the symptoms are nonspecific 
and usually secondary to space-occupying lesions 
(Guo et al, 2013). Plasmacytoma and MM are 
cytologically and immunophenotypically identical. 
However, unlike MM, plasmacytoma is not a 
systemic disease and lacks the characteristic CRAB 
abnormalities such as hypercalcemia, renal failure, 
anemia, and bone lesions (with the exception of 
SBP). Recent studies have shown that there might 
be small cytogenetic differences as well (Bink et al, 
2008). 
Phenotype/cell stem origin 
Monoclonal proliferation of plasma cells. 
Etiology 
The etiology of plasmacytoma remains largely 
unknown. Factors such as viral pathogenesis and 
irritation from inhaled irritants have been noted. 
Genetic factors may also play a role; however, no 
specific loci for the origin of this disease have been 
identified. (Chang et al, 2014) (Cozen et al, 2006). 
Epidemiology 
Plasmacytoma generally occurs more frequently in 
men than in women. Incidence rates anywhere from 
2 to 3 times higher in men than in women have 
been reported (Kilciksiz et al, 2012.) (Corwin et al, 
1979.) (Chang et al, 2014).  
The role that gender plays in incidence rates is 
especially prominent in Caucasians (Corvo et al).  
Age and race also impact the incidence of 
plasmacytoma.  
The median age of diagnosis is 55-65 years old, and 
the incidence rate of plasmacytoma is 
approximately 9 times higher in people over the age 
of 60 than those under the age of 60, indicating that 
plasmacytoma is especially prevalent in older 
populations (Dimopoulos et al, 2000) (Dores et al, 
2009).  
Also, incidence is approximately 30% higher in 
African Americans than in Caucasians, and Asians 
have a 50% decreased lifetime risk of the disease 
(Dores et al, 2009). An increased risk of the disease 
amongst family members of patients with 
SBP/EMP has also been reported (Cozen et al, 
2006). 
Clinics 
Plasmacytoma is a diagnosis of exclusion, as active 
MM must be ruled out.  
The diagnostic criteria for SBP and EMP are as 
follows (Rajkumar, Lancet Oncology, 2014). 
Biopsy proven, single infiltrate of clonal plasma 
cells in bone (SBP) or soft tissue (EMP). 
A bone marrow biopsy showing no evidence of 
infiltration by clonal plasma cells. 
Negative skeletal survey plus MRI/CT spine and 
pelvis except for the solitary lesion. 
Lack of CRAB, which would suggest MM. 
1. Increased Calcium 
2. Renal failure 
3. Anemia   
4. Bone lesions (with the exception of SBP)   
 
 
 
Figure 1:  Stem cell origin of plasmacytoma. This figure demonstrates the origin of the monoclonal proliferation of plasma cells 
that characterizes plasmacytoma and all other plasma cell neoplasms. 
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Figure 2: Left:  Shoulder X-ray showing solitary bone plasmacytoma located in the right shoulder complicated by pathological 
fracture of the head of humerus. Right: Positron emission tomography-computed tomography (PET-CT) scan showing a mass 
occupying the anterior clivus, later identified to be an EMP tumor. 
Solitary plasmacytoma carries a risk of 
transformation in MM of 10% in 3 years. If bone 
marrow aspirate/biopsy shows less than 10% 
involvement by clonal plasma cells, then the 
disease is defined as solitary plasmacytoma with 
minimal marrow involvement, which carries a 60% 
(SBP) or 20% (EMP) risk of transformation in MM 
within 3 years. As space occupying lesions, the 
symptoms of plasmacytoma vary based on the 
location of the tumor. Plasmacytomas located in the 
brain (e.g. solitary craniocerebral plasmacytoma or 
EMP of the brain) can cause headaches, seizures, 
and paralysis while plasmacytomas in the rib may 
cause pain while breathing. 
Generally speaking, a common yet nonspecific 
clinical symptom of SBP is pain. Motor and 
sensory deficits can also occur, secondary to nerve 
impingement from compression fractures (Guo et 
al, 2013). Complications of SBP include 
pathological fractures due to lytic bone disease. 
EMP, on the other hand, usually manifests itself in 
the upper respiratory tract and oral cavity; 
symptoms often include epistaxis, sore throat, 
rhinorrhea, and hemoptysis (Chang et al, 2014) 
(Galieni et al, 2000). 
Cytology 
Plasmacytoma cells are positive for the 
extracellular matrix receptor CD138, and negative 
for CD20, CD3, CD5, BCL-1, and PAX-5 
(Feldman et al, 2015). The expression of CD138 is 
restricted to normal and malignant plasma cells, and 
is commonly used as a marker for identification and 
quantification of plasma cells (O'Connell et al, 
2004). 
 
Figure 3:  Light microscopy image of a plasmacytoma 
showing malignant plasma cells and the presence of Mott 
cells containing intracytoplasmic Russell bodies 
(eosinophilic staining membrane bound body containing 
immunoglobulin) (Image taken from 
https://commons.wikimedia.org/wiki/File:Plasmacytoma1.jp
g)  
Treatment 
Radiotherapy (RT) is generally considered to be the 
best form of treatment for plasmacytoma. While the 
most effective dose has been debated in the 
literature, usually a dose of 40-45 Gray (Gy) is 
required for the best local control without adverse 
toxicity (Dimopoulos et al, 2000). However, it has 
also been reported that there is no dose-response 
relationship for RT of doses greater than 30 Gy 
(Knobel et al, 2006). Plasmacytoma is a particularly 
radiosensitive tumor, and rates of local control in 
EMP from 90-100% have been reported for this 
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treatment alone (Galieni et al, 2000) (Chang et al, 
2014). Surgical resection has proven to be 
beneficial in some cases, though surgery alone is 
usually not recommended as it results in lower rates 
of local control and higher rates of recurrence 
(Kilciksiz et al, 2012, 2012). It shows promise in 
localized tumors that are easily resectable, but is a 
treatment that is often avoided in cases of EMP, as 
a result of the majority of tumors being located in 
the head and neck region with mutilation from 
surgery being a significant risk (Galieni et al, 2000) 
(Kilciksiz et al, 2012). Orthopedic surgery for the 
stabilization or reduction of pathological fractures 
(e.g. open reduction, internal fixation) or the 
restoration of vertebral structure (e.g. kyphoplasty) 
may also be of benefit. The use of chemotherapy 
for this disease has also been reported, but is 
usually reserved for cases in which the 
plasmacytoma has progressed (Corvo et al). 
Particular promise for chemotherapy is seen in 
antiangiogenic compounds such as thalidomide. 
Angiogenesis is highly correlated to progression of 
plasmacytoma to MM, so compounds such as 
thalidomide may play an important role in halting 
this progression (Knobel et al, 2006). Bortezomib 
has also been reported to stimulate bone formation 
and could be of benefit in patients with bone 
disease (Pennisi et al, 2009). 
Evolution 
There are three patterns of failure in the case of 
either SBP or EMP. These are:  
 The development of MM, 
 The development of a new bone lesion without 
progression to MM, 
 A local recurrence. 
Of these three, the progression to MM is the most 
common, with a median time to progression of 2-3 
years for SBP with minimal BM involvement 
(Dimopoulos et al, 2000) (Kilciksiz et al, 2012). 
While varying rates of progression for SBP and 
EMP have been reported, the one commonality is 
that there is a sharp distinction to be drawn between 
SBP and EMP with minimal BM involvement. SBP 
progresses to MM at far higher rates than does 
EMP, with SBP progressing in the range of 
anywhere from 30-75% of cases, and EMP 
progressing in the range of 10-35% of cases 
(Feldman et al, 2015) (Dores et al, 2009.) 
Prognosis 
The median survival time for plasmacytoma 
averages 10 years (Dimopoulos et al, 2000). There 
are a variety of factors that affect the prognosis for 
this disease, and either shorten or lengthen the 
survival time. Higher-grade angiogenesis has been 
shown to lead to a higher rate of progression to MM 
as well as a shorter progression free survival 
(Kilciksiz et al, 2012). A major factor in the 
prognosis of this disease is also which type of 
plasmacytoma is present in the patient. There is a 
large body of literature that shows that EMP carries 
with it a favorable prognosis over SBP (Galieni et 
al, 2000) (Corwin et al, 1979) and that the overall 
and median survival rate for EMP is higher than for 
SBP (Dores et al, 2009). It has been demonstrated 
that EMP progresses to MM at a much lower rate 
than SBP. Galieni et al notes that this favorable 
prognosis might point to EMP having a different 
origin and biological aspects than MM or even SBP 
despite the diseases sharing multiple histologic and 
immunohistochemical similarities. Other factors 
that affect prognosis are age and size of tumor. 
People over the age of 60 with plasmacytoma have 
the least favorable prognosis, whereas those under 
the age of 40 have the most favorable 
(Thumallapally et al, 2017), and tumors larger than 
5 cm were shown to be an unfavorable prognostic 
factor (Knobel et al, 2006). Interestingly, one study 
shows that tumors were larger in the observed SBP 
group than in the EMP group, pointing to a possible 
explanation for the higher rates of progression in 
SBP (Guo et al, 2013). Another study also notes 
that, while the occurrence of plasmacytoma is 
higher in men than in women, men have a 
significantly higher chance of survival. Race, on the 
other hand, did not affect survival in this study, 
despite playing a role in the incidence of the disease 
(Thumallapally et al, 2017). 
Cytogenetics 
Cytogenetics morphological 
Unlike MM, there have only been a few molecular 
studies done on plasmacytoma specifically. Bink et 
al. conducted a study of 38 cases of plasmacytoma 
in an attempt to uncover differences between 
plasmacytoma and MM, and discovered that while 
the two diseases are cytogenetically very similar, 
they differ in the distribution of immunoglobulin 
heavy locus (IGH) translocation partners, with a 
notable lack of t(11;14) in EMP. They found that 
breaks in the 14q32 region were less frequent in 
EMP than MM, and that EMP completely lacked 
the t(11;14)(q13;q32) translocation that occurs in 
15-25% of MM patients. This translocation leads to 
a strong overexpression of CCND1 (cyclin D1), so 
the absence of the translocation in EMP was 
confirmed by complete negativity for cyclin D1 by 
immunohistochemistry. An IGH/FGFR3 fusion 
indicating a t(4;14)(p16;q32) translocation was 
detected in 6/38 (16%) cases. Bink et al. concludes 
that this data may point to the t(11;14) translocation 
being linked to bone marrow involvement, and that 
EMP and MM are likely more than just different 
tissue manifestations of the same plasma cell 
malignancy. 
Plasmacytoma (Solitary bone plasmacytoma, extramedullary 
plasmacytoma) 
Rowell S, et al. 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2019; 23(1) 20 
 
Genes involved and 
proteins 
FGFR3 
Location 
4p16.3 
 
IGH 
Location 
14q32 
This article should be referenced as such: 
Rowell S, Ho M, Bianchi G, Anderson KC. Plasmacytoma 
(Solitary bone plasmacytoma, extramedullary 
plasmacytoma). Atlas Genet Cytogenet Oncol Haematol. 
2019; 23(1):16-20. 
